GC Aesthetics® (GCA), a global provider of aesthetic and reconstructive medical solutions, has announced the appointment of Luigi Ferrari as Non-Executive Chairman of the Board and Patrick Lee as Board Director. The company says these new leadership roles are key to supporting its long-term strategic vision and global growth plans.
The appointments come following a renewed partnership in early 2024 with Hayfin Capital Management, a long-standing investor in GCA. This collaboration has helped energize GCA’s mission to expand worldwide while continuing to focus on innovation and patient safety in breast surgery.
Luigi Ferrari is a respected healthcare executive with extensive leadership experience. He served as CEO of Lima Corporate, a medical device firm in the joint replacement sector, from 2012 to 2022. Under his leadership, Lima was acquired by Enovis Corporation. He also held several senior roles at Orthofix, including President of Global Orthopedics. Ferrari holds a Master’s degree in Management Engineering from the Polytechnic University of Milan and completed Harvard Business School’s Advanced Management Program.
As Chairman, Ferrari will offer strategic guidance and support GCA’s goal to be a global leader in breast aesthetics and reconstruction.
Patrick Lee brings over 30 years of experience in international business and healthcare investment. He previously held senior positions at Advent Venture Partners and Ares Life Sciences, and worked with global pharmaceutical companies. Lee earned his bachelor’s degree from Vassar College and an MBA from Stanford University. His global business experience will help guide GCA’s expansion efforts.
“We are delighted to welcome Luigi and Patrick to the Board of GC Aesthetics,” said CEO Carlos Reis Pinto. “Their expertise and focus on patient-centered innovation will be key as we grow and strengthen our global presence.”
With more than 40 years of experience, operations in over 70 countries, and a strong portfolio backed by long-term clinical data, GC Aesthetics continues to deliver innovative breast care solutions for surgeons and patients worldwide.
Related topics:
